Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Emergent BioSolutions's annualizedNet Income for the quarter that ended in Jun. 2026 was €-625.7 Mil. Emergent BioSolutions's average total tangible assets for the quarter that ended in Jun. 2026 was €738.7 Mil. Therefore, Emergent BioSolutions's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -84.70%.
The historical rank and industry rank for Emergent BioSolutions's Return-on-Tangible-Asset or its related term are showing as below:
FRA:ER4'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -43.76 Med: 5.77 Max: 18.69
Current: -0.93
During the past 13 years, Emergent BioSolutions's highest Return-on-Tangible-Asset was 18.69%. The lowest was -43.76%. And the median was 5.77%.
FRA:ER4's Return-on-Tangible-Asset is ranked worse than 65.28% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs FRA:ER4: -0.93
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Emergent BioSolutions Return-on-Tangible-Asset Related Terms
Emergent BioSolutions Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ER4 vs EOLS, ELTP, AKBA: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -84.70% mean?
Emergent BioSolutions (FRA:ER4) has a Return-on-Tangible-Asset of -84.70% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emergent BioSolutions and its competitors. According to the industry distribution chart, Emergent BioSolutions ranks #658 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Emergent BioSolutions' Return-on-Tangible-Asset too high?
Emergent BioSolutions' current Return-on-Tangible-Asset is -84.70%. Based on the distribution chart, Emergent BioSolutions ranks #658 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Return-on-Tangible-Asset compare to EOLS and ELTP?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #658 out of 1008 companies for Return-on-Tangible-Asset. This places Emergent BioSolutions in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Return-on-Tangible-Asset is -84.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.54 — trading 57.5% above its estimated fair value. The current Return-on-Tangible-Asset is -84.70%. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Return-on-Tangible-Asset is -84.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.54 is trading 57.5% above its estimated GF Value™ of €4.15.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for FRA:ER4:
Return-on-Tangible-Asset: -84.70%
GF Value™: €4.15 vs. price of €6.54 (57.5% above fair value)
No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for FRA:ER4
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ER4 has been successfully added to your 
